PEMOA33 Serological responses to SARS-CoV2 vaccination in people with HIV: the SCAPE-HIV studyPoster exhibitionSARS-Cov2 vaccines
PEMOA34 Seroprevalence of cross-reactive anti-SARS-CoV-2 antibodies in pre-COVID-19 samples collected from Cameroonian women during pregnancy and at deliveryPoster exhibitionImmune responses to SARS-Cov2
PEMOA35 Side-by-side comparison of SARS-CoV-2 neutralizing antibody responses after various COVID-19 vaccine regimensPoster exhibitionSARS-Cov2 vaccines
PEMOA36 Immunogenicity of the BNT 162b2 mRNA vaccine against COVID-19 variants in people living with HIV on antiretroviral therapy in MalaysiaPoster exhibitionSARS-Cov2 vaccines
PEMOA37 Vaccine scheme, age and previous COVID-19 predict humoral response to SARS-CoV-2 vaccination in HIV-infected indivudalsPoster exhibitionSARS-Cov2 vaccines
PEMOA38 People living with HIV who are receiving suppressive antiretroviral therapy mount strong humoral responses to two and three doses of COVID-19 vaccinePoster exhibitionSARS-Cov2 vaccines
PEMOB27 Persistent low-level viremia in the era of dolutegravir in four African countriesPoster exhibitionAdherence
PEMOB28 Safety outcomes among HIV-1 positive Zambian adults receiving Tenofovir Alafenamide combined with Dolutegravir: results from the VISEND clinical trialPoster exhibitionPregnancy (clinical management issues and pharmacokinetics) and contraception
PEMOB29 Selection of cabotegravir dosing regimens for HIV treatment and pre-exposure prophylaxis (PrEP) in adolescents by Leveraging adult dataPoster exhibitionPharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations
PEMOB30 Optimizing DTG uptake amongst children living with HIV in Ikom rural communities attending ART clinic at Comprehensive Health Center (CHC) Ikom, Cross River StatePoster exhibitionARV management strategies in paediatric and adolescent populations
21 - 30 of 2485 items